SCHEMBL4222199

SCHEMBL4222199

CCOC(=O)CN1CCC(CCCOc2cc3ncnc(Nc4cccc(Br)c4)c3cc2OC)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 6/20 0.61
HDAC3 O15379 4/20 0.61
HDAC4 P56524 4/20 0.61
HDAC1 Q13547 4/20 0.61
HDAC7 Q8WUI4 4/20 0.61
HDAC2 Q92769 4/20 0.61
HDAC10 Q969S8 4/20 0.61
HDAC11 Q96DB2 4/20 0.61
HDAC8 Q9BY41 4/20 0.61
HDAC6 Q9UBN7 4/20 0.61
HDAC9 Q9UKV0 4/20 0.61
HDAC5 Q9UQL6 4/20 0.61
FBP1 P09467 3/20 0.58
EGFR P00533 11/20 0.57
ERBB2 P04626 4/20 0.56
KDM4E B2RXH2 1/20 0.56
GAK O14976 1/20 0.56
MAPK13 O15264 1/20 0.56
ABL1 P00519 1/20 0.56
CYP1A2 P05177 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4230216 1.00 KDR (0.61) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4229011 0.98 KDR (0.61) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4224098 0.98 KDR (0.61) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4235071 0.96 KDR (0.60) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4234820 0.96 KDR (0.60) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4226591 0.96 FBP1 (0.60) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4236120 0.96 FBP1 (0.60) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4226538 0.94 KDR (0.64) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL4226644 0.94 KDR (0.64) KDRHDAC3HDAC4HDAC1HDAC7
SCHEMBL7522202 0.92 FBP1 (0.61) KDRHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203683-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-08-13 US disclosed
US-20060063752-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-03-23 US disclosed
EP-1163227-B1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM BOEHRINGER INGELHEIM PHARMA (DE) 2005-09-28 EP disclosed
US-20020177601-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-11-28 US disclosed
EP-1163227-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM Boehringer Ingelheim Pharma KG (DE) 2001-12-19 EP disclosed
WO-2000055141-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS, AND PROCESSES FOR PREPARING THEM BOEHRINGER INGELHEIM PHARMA KG (DE) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203683-A1 BICYCLIC HETEROCYCLES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, THEIR USE, AND PROCESSES FOR PREPARING THEM REN, APC, PKD1 KDR 3805/4885HDAC3 1230/4885HDAC4 3002/4885
US-20060063752-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them REN, APC, PKD1 KDR 3805/4885HDAC3 1230/4885HDAC4 3002/4885
US-20020177601-A1 Bicyclic heterocycles, pharmaceutical compositions containing them, their use, and processes for preparing them PKD1, REN, BDKRB1 KDR 4070/4885HDAC3 1205/4885HDAC4 3534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.